摘要目的: 探讨血清涎液化糖链抗原-6（krebs von den lungen-6,KL-6）在新型冠状病毒感染（COVID-19）中的诊断价值。方法: 选取2023年1月―2月期间入住湖南省人民医院的COVID-19患者51例作为研究对象,根据《新型冠状病毒感染诊疗方案（试行第10版）》的临床分型标准,将其分为重症组27例和非重症组24例,同时收集体检健康者25例作为对照组。比较各组实验室指标变化,采用Pearson相关分析法来进行相关性研究,采用受试者工作特征（ROC）曲线分析KL-6预测COVID-19的诊断效能。结果: 在新冠肺炎重症组患者中,降钙素原（PCT）、C反应蛋白（CRP）、白介素-6（IL-6）明显高于非重症组患者;同时,与对照组相比,新冠患者组白细胞计数（WBC）、中性粒细胞淋巴细胞比值（NLR）、KL-6水平也显著升高;在重症组患者中,WBC、NLR、KL-6明显高于非重症组;WBC、NLR与KL-6之间存在明显正相关;COVID-19患者疾病严重程度与血清KL-6水平成正相关。诊断COVID-19重症患者血清KL-6截断值为362.65 U/mL,对应的的灵敏度为70.4%,特异度为95.8%,约登指数为0.662。结论: 血清KL-6浓度可用于COVID-19的诊断、鉴别和疾病严重程度的评估。
Abstract：Objective To investigate the diagnostic value of serum Krebs von den Lungen-6(KL-6) in patients with COVID-19. Methods A total of 51 COVID-19 patients who were admitted to Hunan Provincial People's Hospital from January to February 2023 were enrolled and classified into severe group (n=27) and non-severe group (n=24) according to the clinical classification criteria of the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 10). In addition, 25 healthy individuals were included as the control group. Laboratory indicators were compared among the groups, and Pearson correlation analysis was used to evaluate the relationship between variables. Receiver operating characteristic (ROC) curve analysis was performed to assess the diagnostic performance of KL-6 for COVID-19. Results In severe cases of COVID-19, procalcitonin (PCT), C-reactive protein (CRP), and interleukin-6(IL-6) were significantly higher than in non-severe cases, while white blood cell count (WBC), neutrophil-to-lymphocyte ratio (NLR), and KL-6 were significantly higher in both non-severe and severe cases compared to the control group. In severe cases, WBC, NLR, and KL-6 were significantly higher than in non-severe cases. There was a significant positive correlation between WBC, NLR, and KL-6. The severity of COVID-19 was positively correlated with serum KL-6 levels. The cutoff value of serum KL-6 for diagnosing severe COVID-19 was 362.65 U/mL, with a sensitivity of 70.4%, specificity of 95.8%, and a Youden index of 0.662. Conclusion Serum KL-6 concentration can be used for the diagnosis, differentiation, and severity assessment of COVID-19.
李婧, 刘颖, 陈杰, 邓中华, 乐杨桦, 曹友德. 血清KL-6水平在新型冠状病毒感染中的诊断价值[J]. 金宝搏官方188学报(医学版), 2023, 20(4): 87-90.
LI Jing, LIU Ying, CHEN Jie, DENG Zhonghua, YUE Yanghua, CAO Youde. The diagnostic value of serum KL-6 levels in COVID-19. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(4): 87-90.
[1] Venkataraman T, Coleman C M, Frieman M B.Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection[J]. J Virol, 2017, 91(12): e00182-00117. [2] Xie L, Liu Y, Xiao Y, et al.Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge[J]. Chest, 2005, 127(6): 2119-2124. [3] Guan W J, Ni Z Y, Hu Y, et al.Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. [4] Vasarmidi E, Tsitoura E, Spandidos D A, et al.Pulmonary fibrosis in the aftermath of the COVID-19 era (Review)[J]. Exp Ther Med, 2020, 20(3): 2557-2560. [5] Ohtsuki Y, Fujita J, Hachisuka Y, et al.Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia[J]. Med Mol Morphol, 2007, 40(4): 198-202. [6] Wang C, Wang Q, Liu T, et al.Krebs von den Lungen-6(KL-6) as a diagnostic marker for pulmonary fibrosis: A systematic review and meta-analysis[J]. Clin Biochem, 2023, 114: 30-38. [7] Ishizaka A, Matsuda T, Albertine K H, et al.Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome[J]. Am J Physiol Lung Cell Mol Physiol, 2004, 286(6): L1088-1094. [8] Nathani N, Perkins G D, Tunnicliffe W, et al.Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome[J]. Crit Care, 2008, 12(1): R12. [9] Hirasawa Y, Kohno N, Yokoyama A, et al.KL-6, a human MUC1 mucin, is chemotactic for human fibroblasts[J]. Am J Respir Cell Mol Biol, 1997, 17(4): 501-507. [10] 中华人民共和国国家卫生健康委员会医政医管局. 关于印发新型冠状病毒感染诊疗方案 (试行第十版) 的通知 (国卫办医急函[2023]4号) [EB/OL]. (2023-01-06)htps: //www. gov. cn/zhengce/zhengceku/2023-01/06/content_5735343. htm. [11] Ponti G, Maccaferri M, Ruini C, et al.Biomarkers associated with COVID-19 disease progression[J]. Crit Rev Clin Lab Sci, 2020, 57(6): 389-399. [12] Tang N, Li D, Wang X, et al.Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia[J]. J Thromb Haemost, 2020, 18(4): 844-847. [13] Zhang G, Zhang J, Wang B, et al.Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a retrospective analysis[J]. Respir Res, 2020, 21(1): 74. [14] Mazaheri T, Ranasinghe R, Al-Hasani W, et al.A cytokine panel and procalcitonin in COVID-19, a comparison between intensive care and non-intensive care patients[J]. PLoS One, 2022, 17(5): e0266652. [15] Ziegler C G K, Allon S J, Nyquist S K, et al. SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues[J]. Cell, 2020, 181(5): 1016-1035. e1019. [16] Inoue Y, Barker E, Daniloff E, et al.Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis[J]. Am J Respir Crit Care Med, 1997, 156(1): 109-115. [17] Jacobs M, Van Eeckhoutte H P, Wijnant S R A, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in alveolar and bronchial epithelium of smokers and COPD subjects[J]. Eur Respir J, 2020, 56(2): 2002378. [18] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J]. Cell, 2020, 181(2): 271-280. e278. [19] Ding M, Zhang Q, Li Q, et al.Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19[J]. Respir Med, 2020, 167: 105981. [20] Cambier M, Henket M, Frix A N, et al.Increased KL-6 levels in moderate to severe COVID-19 infection[J]. PLoS One, 2022, 17(11): e0273107. [21] Frix A N, Schoneveld L, Ladang A, et al.Could KL-6 levels in COVID-19 help to predict lung disease?[J]. Respir Res, 2020, 21(1): 309. [22] D'alessandro M, Bergantini L, Cameli P, et al.Serial KL-6 measurements in COVID-19 patients[J]. Intern Emerg Med, 2021, 16(6): 1541-1545. [23] Awano N, Inomata M, Kuse N, et al.Serum KL-6 level is a useful biomarker for evaluating the severity of coronavirus disease 2019[J]. Respiratory Investigation, 2020, 58(6): 440-447.
2023, Vol. 20 
